{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,4]],"date-time":"2026-05-04T11:59:39Z","timestamp":1777895979528,"version":"3.51.4"},"reference-count":22,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,2,5]],"date-time":"2026-02-05T00:00:00Z","timestamp":1770249600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100014812","name":"Nordic Group BV","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100014812","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","esmoopen.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["ESMO Open"],"published-print":{"date-parts":[[2026,4]]},"DOI":"10.1016\/j.esmoop.2026.106304","type":"journal-article","created":{"date-parts":[[2026,3,17]],"date-time":"2026-03-17T19:36:45Z","timestamp":1773776205000},"page":"106304","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Cost-effectiveness of switching to S-1 after fluoropyrimidine-induced hand-foot syndrome or cardiovascular toxicity in the treatment of metastatic colorectal cancer"],"prefix":"10.1016","volume":"11","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-9045-3630","authenticated-orcid":false,"given":"R.","family":"van Eekelen","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"C.J.A.","family":"Punt","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J.J.M.","family":"Kwakman","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9553-9791","authenticated-orcid":false,"given":"V.M.H.","family":"Coup\u00e9","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"1","key":"10.1016\/j.esmoop.2026.106304_bib1","doi-asserted-by":"crossref","first-page":"442","DOI":"10.4081\/oncol.2020.442","article-title":"Management of cytotoxic chemotherapy-induced hand-foot syndrome","volume":"14","author":"Kwakman","year":"2020","journal-title":"Oncol Rev"},{"issue":"2","key":"10.1016\/j.esmoop.2026.106304_bib2","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1517\/14740338.2011.546342","article-title":"Capecitabine and hand-foot syndrome","volume":"10","author":"Saif","year":"2011","journal-title":"Expert Opin Drug Saf"},{"issue":"4","key":"10.1016\/j.esmoop.2026.106304_bib3","doi-asserted-by":"crossref","first-page":"566","DOI":"10.1093\/annonc\/mdf089","article-title":"First-line oral capecitabine therapy in metastatic colorectal cancer: a favorable safety profile compared with intravenous 5-fluorouracil\/leucovorin","volume":"13","author":"Cassidy","year":"2002","journal-title":"Ann Oncol"},{"key":"10.1016\/j.esmoop.2026.106304_bib4","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1016\/j.ejca.2017.02.009","article-title":"Incidence of capecitabine-related cardiotoxicity in different treatment schedules of metastatic colorectal cancer: a retrospective analysis of the CAIRO studies of the Dutch Colorectal Cancer Group","volume":"76","author":"Kwakman","year":"2017","journal-title":"Eur J Cancer"},{"issue":"2","key":"10.1016\/j.esmoop.2026.106304_bib5","doi-asserted-by":"crossref","DOI":"10.1016\/j.esmoop.2023.101199","article-title":"Fluoropyrimidine-induced hand-foot syndrome and cardiotoxicity: recommendations for the use of the oral fluoropyrimidine S-1 in metastatic colorectal cancer","volume":"8","author":"Punt","year":"2023","journal-title":"ESMO Open"},{"issue":"3","key":"10.1016\/j.esmoop.2026.106304_bib6","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1517\/13543780902729412","article-title":"S-1: a promising new oral fluoropyrimidine derivative","volume":"18","author":"Saif","year":"2009","journal-title":"Expert Opin Investig Drugs"},{"issue":"10","key":"10.1016\/j.esmoop.2026.106304_bib7","doi-asserted-by":"crossref","first-page":"1351","DOI":"10.1080\/14656566.2016.1186649","article-title":"Oral drugs in the treatment of metastatic colorectal cancer","volume":"17","author":"Kwakman","year":"2016","journal-title":"Expert Opin Pharmacother"},{"key":"10.1016\/j.esmoop.2026.106304_bib8","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1016\/j.ejca.2022.02.004","article-title":"Systematic review and non-inferiority meta-analysis of randomised phase II\/III trials on S-1-based therapy versus 5-fluorouracil- or capecitabine-based therapy in the treatment of patients with metastatic colorectal cancer","volume":"166","author":"Derksen","year":"2022","journal-title":"Eur J Cancer"},{"issue":"1","key":"10.1016\/j.esmoop.2026.106304_bib10","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1016\/j.annonc.2022.10.003","article-title":"Metastatic colorectal cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up","volume":"34","author":"Cervantes","year":"2023","journal-title":"Ann Oncol"},{"issue":"3","key":"10.1016\/j.esmoop.2026.106304_bib11","first-page":"229","article-title":"Long-term safety data on S-1 administered after previous intolerance to capecitabine-containing systemic treatment for metastatic colorectal cancer","volume":"21","author":"Punt","year":"2022","journal-title":"Clin Colorectal Cancer"},{"issue":"3","key":"10.1016\/j.esmoop.2026.106304_bib12","doi-asserted-by":"crossref","DOI":"10.1016\/j.esmoop.2022.100427","article-title":"Continuation of fluoropyrimidine treatment with S-1 after cardiotoxicity on capecitabine- or 5-fluorouracil-based therapy in patients with solid tumours: a multicentre retrospective observational cohort study","volume":"7","author":"\u00d6sterlund","year":"2022","journal-title":"ESMO Open"},{"issue":"4","key":"10.1016\/j.esmoop.2026.106304_bib13","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0265767","article-title":"The efficacy and safety of cardio-protective therapy in patients with 5-FU (Fluorouracil)-associated coronary vasospasm","volume":"17","author":"Zafar","year":"2022","journal-title":"PLoS One"},{"key":"10.1016\/j.esmoop.2026.106304_bib14","series-title":"M Sculpher. Decision Modelling for Health Economic Evaluation","author":"Briggs","year":"2011"},{"issue":"6","key":"10.1016\/j.esmoop.2026.106304_bib15","doi-asserted-by":"crossref","first-page":"1288","DOI":"10.1093\/annonc\/mdx122","article-title":"Randomized phase III trial of S-1 versus capecitabine in the first-line treatment of metastatic colorectal cancer: SALTO study by the Dutch Colorectal Cancer Group","volume":"28","author":"Kwakman","year":"2017","journal-title":"Ann Oncol"},{"issue":"5","key":"10.1016\/j.esmoop.2026.106304_bib16","doi-asserted-by":"crossref","first-page":"950","DOI":"10.3109\/0284186X.2013.777158","article-title":"Comparison of treatment outcome in metastatic colorectal cancer patients included in a clinical trial versus daily practice in the Netherlands","volume":"52","author":"Mol","year":"2013","journal-title":"Acta Oncol"},{"issue":"9582","key":"10.1016\/j.esmoop.2026.106304_bib17","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1016\/S0140-6736(07)61086-1","article-title":"Sequential versus combination chemotherapy with capecitabine, irinotecan, and oxaliplatin in advanced colorectal cancer (CAIRO): a phase III randomised controlled trial","volume":"370","author":"Koopman","year":"2007","journal-title":"Lancet"},{"issue":"6","key":"10.1016\/j.esmoop.2026.106304_bib18","doi-asserted-by":"crossref","first-page":"563","DOI":"10.1056\/NEJMoa0808268","article-title":"Chemotherapy, bevacizumab, and cetuximab in metastatic colorectal cancer","volume":"360","author":"Tol","year":"2009","journal-title":"N Engl J Med"},{"issue":"1","key":"10.1016\/j.esmoop.2026.106304_bib19","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1186\/s13561-016-0115-5","article-title":"Systematic review of health state utility values for economic evaluation of colorectal cancer","volume":"6","author":"Jeong","year":"2016","journal-title":"Health Econ Rev"},{"key":"10.1016\/j.esmoop.2026.106304_bib22","series-title":"Lange Nederlanders","year":"2019"},{"issue":"2","key":"10.1016\/j.esmoop.2026.106304_bib26","article-title":"Updated survival analysis of the randomized phase III trial of s-1 versus capecitabine in the first-line treatment of metastatic colorectal cancer by the Dutch Colorectal Cancer Group","volume":"18","author":"Kwakman","year":"2019","journal-title":"Clin Colorectal Cancer"},{"key":"10.1016\/j.esmoop.2026.106304_bib23","series-title":"R: A Language and Environment for Statistical Computing","year":"2024"},{"issue":"9","key":"10.1016\/j.esmoop.2026.106304_bib25","doi-asserted-by":"crossref","first-page":"733","DOI":"10.2165\/00019053-200826090-00004","article-title":"The NICE cost-effectiveness threshold: what it is and what it means","volume":"26","author":"McCabe","year":"2008","journal-title":"Pharmacoeconomics"}],"container-title":["ESMO Open"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2059702926002462?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2059702926002462?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T08:11:59Z","timestamp":1777623119000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2059702926002462"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4]]},"references-count":22,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2026,4]]}},"alternative-id":["S2059702926002462"],"URL":"https:\/\/doi.org\/10.1016\/j.esmoop.2026.106304","relation":{},"ISSN":["2059-7029"],"issn-type":[{"value":"2059-7029","type":"print"}],"subject":[],"published":{"date-parts":[[2026,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Cost-effectiveness of switching to S-1 after fluoropyrimidine-induced hand-foot syndrome or cardiovascular toxicity in the treatment of metastatic colorectal cancer","name":"articletitle","label":"Article Title"},{"value":"ESMO Open","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.esmoop.2026.106304","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Author(s). Published by Elsevier Ltd on behalf of European Society for Medical Oncology.","name":"copyright","label":"Copyright"}],"article-number":"106304"}}